Cite
HARVARD Citation
Unseld, M. et al. (2021). A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study. International journal of cancer. 148 (6), pp. 1452-1461. [Online].